<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1503">
  <stage>Registered</stage>
  <submitdate>17/12/2003</submitdate>
  <approvaldate>17/12/2003</approvaldate>
  <actrnumber>ACTRN12607000012471</actrnumber>
  <trial_identification>
    <studytitle>Adjuvant Therapy for Postmenopausal Patients with Operable Breast Cancer who have Estrogen Receptor or Progesterone Receptor Positive Tumors.
Tamoxifen vs. Letrozole vs. Tamoxifen followed by Letrozole vs. Letrozole followed by Tamoxifen</studytitle>
    <scientifictitle>A phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor (ER and/or PgR) positive tumours</scientifictitle>
    <utrn />
    <trialacronym>IBCSG 18-98 / BIG 1-98(Letrozole)</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR447</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients are randomised to one of the following treatment arms:
Tamoxifen (20mg orally once a day) for 5 years
Vs
Letrozole (2.5mg orally once a day) for 5 years
Vs
Tamoxifen (20mg orally once a day) for 2 years, followed by letrozole (2.5mg orally once a day) for 3 years.
Vs
Letrozole (2.5mg orally once a day) for 2 years, followed by tamoxifen (20mg orally once a day) for 3 years.</interventions>
    <comparator>to be confirmed</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is disease free survival.  Disease free-survival is defined as the time from randomisation to recurrence (including recurrence restricted to the breast after breast conserving treatment), metastasis, appearance of a second primary tumour, or death from any cause, whichever occurs first.</outcome>
      <timepoint>Patients are assessed by clinicians for progression of disease and survival every 6 months until 5 years from randomisation and then annually thereafter for life.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The secondary endpoint is overall survival and safety.</outcome>
      <timepoint>Patients are assessed by clinicians for survival every 6 months for the first 5 years on study and annually thereafter for life.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patients are also assessed for tolerability of treatment and side effects</outcome>
      <timepoint>Every 6 months during the first five years on study or until 30 days after treatment is completed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Accrual, toxicity and deaths will be monitored.</outcome>
      <timepoint>to be confirmed</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Compliant postmenopausal women with histologically proven breast cancer who have had either a total mastectomy or a lesser procedure who are classified as pT1-3 or pT4b, Nx, Nsentinel-ve, N0-2, M0, and have oestrogen receptor and/or progesterone receptor positive tumours (ER/PR=10 fmol/mg cytosol protein or =10% of tumour cells positive by immunocytochemical assay);  judged suitable for endocrine treatment; adequate marrow function, adequate renal and hepatic function; written and dated informed consent; geographically accessible for follow up; informed of data and material transfer and handling.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with distant metastases.  Bilateral breast cancer except in situ lesions of the contralateral breast.  Patients with prior ipsilateral in situ breast cancer.  Patients with previous history of concomitant other (not breast) malignancy within the past 5 years except adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous malignancy must have been disease free for five years.  Patients receiving adjuvant chemotherapy at randomisation. Patients with other non-malignant systemic diseases.  Patients treated with systemic investigational drugs within the past 30 days or topical investigational drugs within the past 7 days.  History of non-compliance to medical regimens and patients who are considered potentially unreliable.  Patients known to be HIV positive.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The Australian New Zealand Breast Cancer Trials Group Statistical Centre at the National Health Medical Research Council Clinical Trials Centre, University of Sydney provided a central randomisation service by fax for all Australian and New Zealand institutions. At the time of study entry all participants were allocated a treatment arm via a web-based randomization system and treatment was supplied in accordance with the allocated drug kit code.</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects, investigators (clinicians treating the patients) and pharmacists are blinded to the study treatment</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/04/1999</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>6193</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharma AG, Basel</primarysponsorname>
    <primarysponsoraddress>to be confirmed</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Australian New Zealand Breast Cancer Trials Group</fundingname>
      <fundingaddress>As the trial is now complete. No further information will be added due to time constraints.</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharma AG, Basel</fundingname>
      <fundingaddress>As the trial is now complete. No further information will be added due to time constraints.</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>International Breast Cancer Study Group</sponsorname>
      <sponsoraddress>As the trial is now complete. No further information will be added due to time constraints.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australian New Zealand Breast Cancer Trials Group</sponsorname>
      <sponsoraddress>As the trial is now complete. No further information will be added due to time constraints.</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Tamoxifen is a hormone tablet that improves cure rates in women with early breast cancer.  Letrozole is a new hormone tablet that has recently been shown to work in advanced breast cancer.  This international trial will determine if in women with early breast cancer, Letrozole is as good or better than tamoxifen, and whether taking both together is better still.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Launceston General Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Maroondah Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Cancer Care Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Misericordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Women's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Hobart Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Toowoomba Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Waikato Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Western Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor John F Forbes</name>
      <address>Australian New Zealand Breast Cancer Trials Group Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 4985 0113</phone>
      <fax>+ 61 2 4960 1539</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Administrative Officer, Data Management</name>
      <address>Australian New Zealand Breast Cancer Trials Group Operations Office
Department of Surgical Oncology
Locked Bag 7
Hunter Region Mail Centre
Newcastle NSW 2310</address>
      <phone>+61 2 49850166</phone>
      <fax>+61 2 49850141</fax>
      <email>enquiries@anzbctg.newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>